Analysis of isocitrate dehydrogenase-1/2 gene mutations in gliomas / 中华医学杂志(英文版)
Chinese Medical Journal
; (24): 3697-3705, 2010.
Article
Dans En
| WPRIM
| ID: wpr-336561
Responsable en Bibliothèque :
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To highlight recent researches which may show promise for histomolecular classification and new treatments for gliomas.</p><p><b>DATA SOURCES</b>All articles cited in this review were mainly searched from PubMed, which were published in English from 1996 to 2010.</p><p><b>STUDY SELECTION</b>Original articles and critical reviews selected were relevant to the isocitrate dehydrogenase-1/2 mutation in gliomas and other tumors.</p><p><b>RESULTS</b>Extraordinary high rates of somatic mutations in isocitrate dehydrogenase-1/2 occur in the majority of World Health Organization grade II and grade III gliomas as well as grade IV secondary glioblastomas. Isocitrate dehydrogenase-1/2 mutations are associated with younger age at diagnosis and a better prognosis in patients with mutated tumors. The functional role of isocitrate dehydrogenase-1/2 mutations in the pathogenesis of gliomas is still unclear.</p><p><b>CONCLUSION</b>Isocitrate dehydrogenase-1/2 mutations define a specific subtype of gliomas and may have great significance in the diagnosis, prognosis, and treatment of patients with these tumors.</p>
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Anatomopathologie
/
Physiologie
/
Pronostic
/
Tumeurs du cerveau
/
Gènes p53
/
Facteurs âges
/
Grading des tumeurs
/
Génétique
/
Gliome
/
Glutarates
Type d'étude:
Prognostic_studies
Limites du sujet:
Adult
/
Humans
langue:
En
Texte intégral:
Chinese Medical Journal
Année:
2010
Type:
Article